BOSTON, Feb. 15 (TNSJou) -- The Dana-Farber Cancer Institute issued the following news release: Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. The survival benefit demonstrates that an immune checkpoint inhibitor together with a targeted kinas  more

WALTHAM, Massachusetts, Feb. 11 -- The New England Journal of Medicine, a peer-reviewed medical journal from the the Massachusetts Medical Society that says it delivers research and interactive clinical content to physicians, educators and the global medical community, published research articles, including the following topics, in its Feb. 11, 2021 edition: Perspective: * The Future of Drug-Pricing Transparency * Becoming a Physician: A Shared Evaluation Platform for Medical Training * Lear  more